Researchers
Klunk, William E MD
University of Pittsburgh
INCLUDE Grants
Neurodegeneration in Aging Down Syndrome (NiAD): A Longitudinal Study of Cognition and Biomarkers of Alzheimer’s Disease
Grant Number
3U01AG051406-04S3
NIH Institute
NIA
Mechanism
U01
Adults with Down syndrome (DS) are at an extremely high risk for developing Alzheimer's disease (AD), with most individuals over age 40 evidencing neurofibrillary tangles and neuritic plaques (which are thought to be associated with the eventual appearance of AD symptoms). The goal of the current application is to recruit and follow 180 adults with DS and 40 biomarker controls to enable the identification of the longitudinal progression of AD in adults with DS using clinical, cognitive, imaging and genetic and biochemical biomarkers. This data is not only necessary to deepen our understanding of the pathophysiology of AD in DS, but may also offer information that will prove useful in the design of treatment trials to slow or prevent AD in DS.
Publications
-
Alzheimer's & dementia : the journal of the Alzheimer's Association
Development and evaluation of image preprocessing pipelines for the Centiloid method on Down Syndrome data. -
Alzheimer's & dementia : the journal of the Alzheimer's Association
Characterizing the emergence of amyloid and tau burden in Down syndrome. -
Neurobiology of aging
Amyloid- β and tau deposition influences cognitive and functional decline in Down syndrome. -
JAMA neurology
Detection of Brain Tau Pathology in Down Syndrome Using Plasma Biomarkers. -
Neurobiology of aging
Support vector machine learning and diffusion-derived structural networks predict amyloid quantity and cognition in adults with Down’s syndrome. -
Alzheimer's & dementia (Amsterdam, Netherlands)
Cortical atrophy and amyloid and tau deposition in Down syndrome: A longitudinal study. -
NeuroImage. Clinical
White matter microstructure associations to amyloid burden in adults with Down syndrome.